Hyperparathyroidism: Time to reconsider current clinical decision paradigms?

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 9, 2008, Pages 3302-3304

  Fuleihan, Ghada El Hajj ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIMIMETIC AGENT; CALCIUM; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE;

BODY MASS; BONE DENSITY; BONE MASS; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; DENSITOMETRY; DISEASE COURSE; EDITORIAL; FEMUR NECK; FOLLOW UP; HEALTH CARE ORGANIZATION; HUMAN; HYPERCALCIURIA; KIDNEY DYSFUNCTION; LUMBAR SPINE; MORPHOMETRICS; MORTALITY; NEOPLASM; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROIDECTOMY; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; TRABECULAR BONE;

EID: 51649116446     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2008-1305     Document Type: Editorial

References (22)

1. Albright F, Reifenstein EC 1948 The parathyroid glands and metabolic bone disease. Baltimore: Williams & Wilkins Co.
2. Wermers RA, Khosla S, Atkinson EJ, Achenbach SJ, Oberg AL, Grant CS, Melton 3rd LJ 2006 Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res 21:171-177
3. Bilezikian JP, Silverberg SJ 2004 Clinical practice. Asymptomatic primary hyperparathyroidism. N Engl J Med 350:1746-1751
4. Scholz DA, Purnell DC 1981 Asymptomatic primary hyperparathyroidism: 10-year prospective study. Mayo Clin Proc 56:473-478
5. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP 1999 A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med 341:1249-1255
6. Potts Jr JT, Franklin JE, Aurbach GD, Bilezikian JP, Raisz Lg, Eds 1991 Proceedings of the NIH consensus development conference on diagnosis and management of asymptomatic primary hyperparathyroidism. J Bone Miner Res Suppl 2:S1-S166
7. Bilezikian JP, Potts JT, El-Hajj Fuleihan G, Kleerekoper M, Neer R, Peacock M, Rastad J, Silverberg SJ, Udelsman R, Wells SA 2002 Summary statement from a workshop on asymptomatic hyperparathyrodisim: a perspective for the 21st century. J Clin Endocrinol Metab 87:353-361
8. Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E, Udesky J, Silverberg SJ 2008 The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 93:3462-3470
9. Rao DS, Wilson RJ, Kleerekoper M, Parfitt AM 1988 Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. J Clin Endocrinol Metab 67:1294-1298
10. Guo CY, Thomas WE, al-Dehaimi AW, Assiri AM, Eastell R 1996 Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab 81:3487-3491
11. Silverberg SJ, Locker FG, Bilezikian JP 1996 Vertebral osteopenia: a new indication for surgery in primary hyperparathyroidism. J Clin Endocrinol Metab 81:4007-4012
12. Eriksen EF 2002 Primary hyperparathyroidism: lessons from bone histomorphometry. J Bone Miner Res Suppl 2:N95-N97
13. Khosla S, Melton 3rd J 2002 Fracture risk in primary hyperparathyroidism. J Bone Miner Res Suppl 2:N103-N107
14. Larsson K, Ljunghall S, Krusemo UB, Naessén T, Lindh E, Persson I 1993 The risk of hip fractures in patients with primary hyperparathyroidism: a population-based cohort study with a follow-up of 19 years. J Intern Med 234:585-593
15. Roschger P, Dempster DW, Zhou H, Paschalis EP, Silverberg SJ, Shane E, Bilezikian JP, Klaushofer K 2007 New observations on bone quality in mild primary hyperparathyroidism as determined by quantitative backscattered electron imaging. J Bone Miner Res 22:717-723
16. Nilsson IL, Yin L, Lundgren E, Rastad J, Ekbom A 2002 Clinical presentation of primary hyperparathyroidism in Europe: nationwide cohort analysis on mortality from nonmalignant causes. J Bone Miner Res Suppl 2:N68-N74
17. Bollerslev J, Jansson S, Mollerup CL, Nordenström J, Lundgren E, Tørring O, Varhaug JE, Baranowski M, Aanderud S, Franco C, Freyschuss B, Isaksen GA, Ueland T, Rosen T 2007 Medical observation, compared with parathyroid-ectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab 92:1687-1692
18. Siilin H, Rastad J, Ljunggren O, Lundgren E 2008 Disturbances of calcium homeostasis consistent with mild primary hyperparathyroidism in premenopausal women and associated morbidity. J Clin Endocrinol Metab 93:47-53
19. Ambrogini E, Cetani F, Cianferotti L, Vignali E, Banti C, Viccica G, Oppo A, Miccoli P, Berti P, Bilezikian JP, Pinchera A, Marcocci C 2007 Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J Clin Endocrinol Metab 92:3114-3121
20. Utiger RD 1999 Treatment of primary hyperparathyroidism. N Engl J Med 341:1301-1302
21. International Workshop on Primary Hyperparathyroidism, Orlando, FL, 2008; http://www.ectsoc.org/phprogramme.pdf (accessed June 24, 2008)
22. Nakchbandi IA, Lang R, Kinder B, Insogna KL 2008 The role of the receptor activator of nuclear factor-κB ligand/osteoprotegerin cytokine system in primary hyperparathyroidism. J Clin Endocrinol Metab 93:967-973